NeuroSense Therapeutics Ltd.
NRSN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001875091
No open-market purchases or sales by NeuroSense Therapeutics Ltd. insiders were filed in the last 90 days; 12 institutions reported holding it in 13F filings for Q2 2026, worth $285.7K in total; no superinvestor holds it.
Other share classesNRSNW
13F holders, Q4 2025
Institutional positions in NeuroSense Therapeutics Ltd. as of Dec 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 13
- +3 vs. Q3 2025
- Shares held
- 346.1K
- +68.2K (+24.5%) vs. Q3 2025
- Total value
- $266.2K
- −$80.6K (−23.2%) vs. Q3 2025
- New holders
- 5
- 3 more added
- Sold out
- 2
- 1 more reduced
Compare with Q3 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting NRSN on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 12 | $285.7K |
| Q1 2026 | 13 | $286.7K |
| Q4 2025 | 13 | $266.2K |
| Q3 2025 | 10 | $346.8K |
| Q2 2025 | 17 | $964.4K |
| Q1 2025 | 11 | $180.8K |
| Q4 2024 | 13 | $775.8K |
| Q3 2024 | 7 | $285.9K |
| Q2 2024 | 7 | $1.87M |
| Q1 2024 | 8 | $303.9K |
| Q4 2023 | 8 | $110.6K |
| Q3 2023 | 5 | $554.1K |
| Q2 2023 | 6 | $2.34M |
| Q1 2023 | 5 | $243.4K |
| Q4 2022 | 5 | $41.6K |
| Q3 2022 | 5 | $132.0K |
| Q2 2022 | 7 | $733.0K |
| Q1 2022 | 9 | $694.0K |
| Q4 2021 | 5 | $380.0K |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2025
Shares, value and share of portfolio for each institution holding NeuroSense Therapeutics Ltd.; share changes are against Q3 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Yorkville Advisors Global, LP | 100,000 | $76.9K | 0.05% | +100,000 | New |
| Two Sigma Investments, LP | 51,545 | $39.6K | 0.00% | +30,459+144.5% | Added |
| Meitav Dash Investments Ltd | 40,000 | $30.8K | 0.00% | 00.0% | Unchanged |
| GTS Securities LLC | 35,753 | $27.5K | 0.00% | +35,753 | New |
| UBS Group AG | 30,871 | $23.7K | 0.00% | +16,212+110.6% | Added |
| Commonwealth Equity Services, LLC | 22,775 | $17.5K | 0.00% | +1,695+8.0% | Added |
| Squarepoint Ops LLC | 17,926 | $13.8K | 0.00% | −77,449−81.2% | Reduced |
| Pathstone Holdings, LLC | 16,528 | $12.7K | 0.00% | +16,528 | New |
| Geode Capital Management, LLC | 15,870 | $12.2K | 0.00% | 00.0% | Unchanged |
| Creative Planning | 11,911 | $9.16K | 0.00% | +11,911 | New |
| SBI Securities Co., Ltd. | 1,455 | $1.12K | 0.00% | 00.0% | Unchanged |
| Jones Financial Companies LLLP | 1,000 | $769 | 0.00% | 00.0% | Unchanged |
| Jessup Wealth Management, Inc | 500 | $385 | 0.00% | +500 | New |
| Morgan Stanley | 0 | $0 | 0.00% | −66,400−100.0% | Sold out |
| CWM, LLC | 0 | $0 | 0.00% | −1,000−100.0% | Sold out |